Volume 24, Issue 4 (3-2022)
Hakim 2022, 24(4): 347-358 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Daroudi R, Imanpour M, Nourizadeh Tehrani P. effectiveness of Mulnopiravir, Paxlovid and Floxamine in the treatment of patients with Covid-19: A review study. Hakim 2022; 24 (4) :347-358
URL: http://hakim.tums.ac.ir/article-1-2189-en.html
URL: http://hakim.tums.ac.ir/article-1-2189-en.html
1- National Center for Health Insurance Research, Tehran, Iran.
2- M.Sc. of Health Economics, Department of Health Management and Economics, School of Management and Medical Information, Isfahan University of Medical Sciences, Isfahan, Iran.
3- M.Sc. of Health Economics, Department of Health Management, policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. ,pedramnzt@yahoo.com
2- M.Sc. of Health Economics, Department of Health Management and Economics, School of Management and Medical Information, Isfahan University of Medical Sciences, Isfahan, Iran.
3- M.Sc. of Health Economics, Department of Health Management, policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. ,
Abstract: (415 Views)
Introduction: since 2021, one of the most important global public health challenges has been the COVID-19 coronavirus pandemic. Three of the drugs that have been introduced to treat patients with COVID-19 in mild to moderate stage include paxlovid, molnopyravir and fluoxamine. The aim of this study was to evaluate the effectiveness of these drugs in the treatment of patients with COVID-19 in mild to moderate stage.
Methods: This study was done through umbrella review and in order to conduct a systematic review in PubMed, CoChrane and Google Scholar databases with appropriate vocabulary. The articles were evaluated for quality using the CASP checklist. The study extracted outcomes related to the drugs, such as hospitalization and death rates due to COVID-19, as well as any side effects reported in the studies.
Results: Based on the findings, Paxlovid reduced the risk of death and the likelihood of hospitalization by about 88%, while fluvoxamine reduced the likelihood of hospitalization by about 31%. The use of Molnopyravir reduces the risk of hospitalization or death by about 30%. However, the efficacy of this drug decreased with the expansion of the omecaron strain.
Conclusion: Paxlovid drug is effective in reducing the possibility of hospitalization and mortality of patients with covid-19 in the mild to moderate stage. However, regarding the effectiveness of Molnopiravir and Fluxamine, the level of evidence is low and more research is needed.
Methods: This study was done through umbrella review and in order to conduct a systematic review in PubMed, CoChrane and Google Scholar databases with appropriate vocabulary. The articles were evaluated for quality using the CASP checklist. The study extracted outcomes related to the drugs, such as hospitalization and death rates due to COVID-19, as well as any side effects reported in the studies.
Results: Based on the findings, Paxlovid reduced the risk of death and the likelihood of hospitalization by about 88%, while fluvoxamine reduced the likelihood of hospitalization by about 31%. The use of Molnopyravir reduces the risk of hospitalization or death by about 30%. However, the efficacy of this drug decreased with the expansion of the omecaron strain.
Conclusion: Paxlovid drug is effective in reducing the possibility of hospitalization and mortality of patients with covid-19 in the mild to moderate stage. However, regarding the effectiveness of Molnopiravir and Fluxamine, the level of evidence is low and more research is needed.
Keywords: Effectiveness, Mulnopiravir, Paxlovid, Fluvoxamine, Meta-Analysis, Systematic Review, COVID-19
Type of Study: Review |
Subject:
General
Received: 2023/04/7 | Accepted: 2022/03/1 | Published: 2022/03/1
Received: 2023/04/7 | Accepted: 2022/03/1 | Published: 2022/03/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
